Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.50 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 2/20 | 0.45 |
| ▸ | HTR2B | P41595 | 2/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2797649 | 0.94 | TSHR (0.52) | SYKHTR2BTSHRCYP2D6KDM4E | |
| SCHEMBL4154959 | 0.91 | LTA4H (0.53) | HTR2CHTR2BPOLBCYP2D6KDM4E | |
| SCHEMBL723902 | 0.88 | LTA4H (0.42) | KDM4ELTA4H | |
| SCHEMBL31068420 | 0.87 | POLB (0.51) | SYKTSHRPOLBKDM4ENPC1 | |
| SCHEMBL17075646 | 0.86 | KDM4E (0.48) | SYKHTR2CHTR2BTSHRPOLB | |
| SCHEMBL13957871 | 0.86 | POLB (0.44) | SYKHTR2CHTR2BTSHRPOLB | |
| SCHEMBL14758443 | 0.86 | TSHR (0.62) | HTR2CHTR2BTSHRPOLBCYP2D6 | |
| SCHEMBL22636056 | 0.86 | ALDH1A1 (0.44) | SYKHTR2CHTR2BTSHRPOLB | |
| SCHEMBL430271 | 0.84 | ALDH1A1 (0.43) | SYKTSHRPOLBNPC1RAB9A | |
| SCHEMBL28502391 | 0.83 | FGFR3 (0.43) | TSHRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110520416-B | Polysubstituted pyridone derivative, preparation method and medical application thereof | 北京越之康泰生物医药科技有限公司 | 2022-06-03 | — | — | CN | disclosed |
| US-20220002277-A1 | PYRIDONE DERIVATIVE HAVING TETRAHYDROPYRANYLMETHYL GROUP | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-01-06 | — | — | US | disclosed |
| US-11208403-B2 | Pyridone derivatives having tetrahydropyranylmethyl groups | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-12-28 | — | — | US | disclosed |
| EP-3168219-B1 | PYRIDONE DERIVATIVE HAVING TETRAHYDROPYRANYL METHYL GROUP | DAIICHI SANKYO CO LTD (JP) | 2021-03-31 | — | — | EP | disclosed |
| CN-110520416-A | Polysubstituted pyridine ketones derivant, preparation method and its medical usage | BEIJING YUEZHIKANGTAI BIOMEDICINES CO LTD | 2019-11-29 | — | — | CN | disclosed |
| US-10442797-B2 | Pyridone derivatives having tetrahydropyranylmethyl groups | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2019-10-15 | — | — | US | disclosed |
| EP-2925319-B1 | MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES | UNIV ROCHESTER (US) | 2019-01-09 | — | — | EP | disclosed |
| US-20180148436-A2 | PYRIDONE DERIVATIVES HAVING TETRAHYDROPYRANYLMETHYL GROUPS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-05-31 | — | — | US | disclosed |
| US-20180148436-A2 | PYRIDONE DERIVATIVES HAVING TETRAHYDROPYRANYLMETHYL GROUPS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-05-31 | — | — | US | disclosed |
| US-9814704-B2 | Substituted pyrrolo[2,3-b]pyridines as MLK inhibitors | THE UNIVERSITY OF ROCHESTER (US) | 2017-11-14 | — | — | US | disclosed |
| US-20130203755-A1 | BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE | UNIVERSITY OF ROCHESTER (US) | 2013-08-08 | — | — | US | disclosed |
| EP-2576549-A2 | BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE | University of Rochester (US) | 2013-04-10 | — | — | EP | disclosed |
| WO-2012167733-A1 | SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS | HUTCHISON MEDIPHARMA LIMITED (CN) | 2012-12-13 | — | — | WO | disclosed |
| EP-2155201-B1 | QUINOXALINE DERIVATIVES AS INHIBITORS OF THE TYROSINE KINASE ACTIVITY OF JANUS KINASES | NOVARTIS AG (CH) | 2012-08-01 | — | — | EP | disclosed |
| US-8193189-B2 | Quinoxaline derivatives as tyrosine kinase activity inhibitors | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| US-20120053175-A1 | MLK INHIBITORS AND METHODS OF USE | UNIVERSITY OF ROCHESTER (US) | 2012-03-01 | — | — | US | disclosed |
| WO-2011149950-A2 | BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE | UNIVERSITY OF ROCHESTER (US) | 2011-12-01 | — | — | WO | disclosed |
| EP-2379561-A2 | MLK INHIBITORS AND METHODS OF USE | University Of Rochester (US) | 2011-10-26 | — | — | EP | disclosed |
| US-20100168062-A1 | Quinoxaline Derivatives as Tyrosine Kinase Activity Inhibitors | NOVARTIS AG | 2010-07-01 | — | — | US | disclosed |
| WO-2010068483-A2 | MLK INHIBITORS AND METHODS OF USE | UNIVERSITY OF ROCHESTER (US) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053175-A1 | MLK INHIBITORS AND METHODS OF USE | MAP3K20, MAP3K2, MAP3K7 | SYK 1715/4885LRRK2 397/4885HTR2C 1255/4885 |
| US-20220002277-A1 | PYRIDONE DERIVATIVE HAVING TETRAHYDROPYRANYLMETHYL GROUP | AXL, TYRO3, LCK | SYK 10/4885LRRK2 39/4885HTR2C 2518/4885 |
| US-10442797-B2 | Pyridone derivatives having tetrahydropyranylmethyl groups | AXL, TYRO3, PDXK | SYK 27/4885LRRK2 31/4885HTR2C 2329/4885 |
| US-20100168062-A1 | Quinoxaline Derivatives as Tyrosine Kinase Activity Inhibitors | JAK2, JAK1, JAK3 | SYK 18/4885LRRK2 309/4885HTR2C 994/4885 |
| US-11208403-B2 | Pyridone derivatives having tetrahydropyranylmethyl groups | AXL, TYRO3, PDXK | SYK 27/4885LRRK2 31/4885HTR2C 2329/4885 |
| US-20130203755-A1 | BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE | MAP2K2, MAP2K7, CHKB | SYK 2518/4885LRRK2 400/4885HTR2C 644/4885 |
| US-20180148436-A2 | PYRIDONE DERIVATIVES HAVING TETRAHYDROPYRANYLMETHYL GROUPS | AXL, TYRO3, PDXK | SYK 27/4885LRRK2 31/4885HTR2C 2329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.